UHS - Universal Health Services, Inc.
NYSE
->
Healthcare
->
Medical Care Facilities
King of Prussia,
United States
Type: Equity
UHS price evolution
UHS
| (in millions $) | 31 Dec 2023 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $119.44 | $80.77 | $79.45 | $109.97 |
| Short term investments | ||||
| Net receivables | $2238.26 | $2234.34 | $2103.48 | $2032.18 |
| Inventory | $216.99 | $214.59 | $215.38 | $216.24 |
| Total current assets | $2811.35 | $2753 | $2624.71 | $2559.1 |
| Long term investments | ||||
| Property, plant & equipment | $6558.49 | $6530.98 | $6474.33 | $6412.33 |
| Goodwill & intangible assets | $3932.41 | $3912.12 | $3929.72 | $3913.91 |
| Total noncurrent assets | $11156.25 | $11120.47 | $11107.59 | $10996.86 |
| Total investments | ||||
| Total assets | $13967.6 | $13873.47 | $13732.31 | $13555.96 |
| Current liabilities | ||||
| Accounts payable | $613.97 | $1783.46 | $1843.38 | $1636.1 |
| Deferred revenue | ||||
| Short long term debt | $198.29 | $199.21 | $185.01 | $169.42 |
| Total current liabilities | $2013.35 | $1989.82 | $2035.35 | $1863.38 |
| Long term debt | $5168.34 | $4796.07 | $4992.78 | $5103.81 |
| Total noncurrent liabilities | $5757.54 | $5777.17 | $5568.2 | $5640.16 |
| Total debt | $5366.63 | $5383.83 | $5177.79 | $5273.23 |
| Total liabilities | $7770.89 | $7808.56 | $7603.55 | $7503.54 |
| Shareholders' equity | ||||
| Retained earnings | $6139.04 | $6074.5 | $6073.05 | $6016.45 |
| Other shareholder equity | $9.29 | $6064.91 | $13.43 | -$5.05 |
| Total shareholder equity | $6149 | $6064.91 | $6087.18 | $6012.11 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $119.44 | $102.82 | $115.3 | $1224.49 |
| Short term investments | ||||
| Net receivables | $2238.26 | $2017.72 | $1746.63 | $1728.93 |
| Inventory | $216.99 | $218.52 | $206.84 | $190.42 |
| Total current assets | $2811.35 | $2537.34 | $2263.56 | $3281.87 |
| Long term investments | $157.06 | |||
| Property, plant & equipment | $6558.49 | $6373.11 | $6241.75 | $5709.64 |
| Goodwill & intangible assets | $3932.41 | $3909.46 | $3962.62 | $3882.72 |
| Total noncurrent assets | $11156.25 | $10956.85 | $10829.99 | $10195.01 |
| Total investments | ||||
| Total assets | $13967.6 | $13494.19 | $13093.54 | $13476.88 |
| Current liabilities | ||||
| Accounts payable | $613.97 | $636.6 | $658.9 | $570.52 |
| Deferred revenue | ||||
| Short long term debt | $198.29 | $149.22 | $112.89 | $391.79 |
| Total current liabilities | $2013.35 | $1914.42 | $1984.11 | $2481.04 |
| Long term debt | $5168.34 | $4726.53 | $4446.5 | $3802.56 |
| Total noncurrent liabilities | $5757.54 | $5614.42 | $4916.38 | $4593.87 |
| Total debt | $5366.63 | $5271.28 | $4559.4 | $4194.35 |
| Total liabilities | $7770.89 | $7573.61 | $6900.49 | $7074.91 |
| Shareholders' equity | ||||
| Retained earnings | $6139.04 | $5929.54 | $6058.6 | $6268.18 |
| Other shareholder equity | $9.29 | -$9.67 | $30.29 | $48.12 |
| Total shareholder equity | $6149 | $5920.58 | $6089.66 | $6317.15 |
| (in millions $) | 31 Dec 2023 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3703.55 | $3562.77 | $3467.52 | |
| Cost of revenue | ||||
| Gross Profit | $3703.55 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $1799.01 | |||
| Total operating expenses | $3372.35 | $3277.42 | $3188.82 | |
| Operating income | $331.2 | |||
| Income from continuing operations | ||||
| EBIT | $331.47 | |||
| Income tax expense | $61.5 | $52.5 | $51.73 | |
| Interest expense | $53.59 | -$53.38 | -$50.88 | |
| Net income | ||||
| Net income | $216.38 | $166.94 | $162.99 | |
| Income (for common shares) | $216.38 | |||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $14281.98 | $13399.37 | $12642.12 | $11558.9 |
| Cost of revenue | ||||
| Gross Profit | $14281.98 | $13399.37 | $12642.12 | $11558.9 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $7107.48 | $6762.26 | $6163.94 | $5613.1 |
| Total operating expenses | $13106.59 | $12395.82 | $11279.02 | $10200.54 |
| Operating income | $1175.38 | $1003.55 | $1363.09 | $1358.35 |
| Income from continuing operations | ||||
| EBIT | $1145.59 | $1011.78 | $1380.94 | $1349.53 |
| Income tax expense | $221.12 | $209.28 | $305.68 | $299.29 |
| Interest expense | $206.67 | $126.89 | $83.67 | $106.28 |
| Net income | ||||
| Net income | $717.79 | $675.61 | $991.59 | $943.95 |
| Income (for common shares) | $717.79 | $675.61 | $991.59 | $943.95 |
| (in millions $) | 31 Dec 2023 | 30 Oct 2023 | 30 Jun 2023 | 1 May 2023 |
|---|---|---|---|---|
| Net income | $216.38 | $171.31 | ||
| Operating activities | ||||
| Depreciation | $145.48 | $143.74 | ||
| Business acquisitions & disposals | $0.5 | $10.7 | ||
| Stock-based compensation | $22.02 | $22.1 | ||
| Total cash flows from operations | $452.43 | $362.95 | ||
| Investing activities | ||||
| Capital expenditures | -$206.39 | -$167.91 | ||
| Investments | -$32.97 | -$12.49 | ||
| Total cash flows from investing | -$238.85 | -$524.43 | -$169.7 | -$178.31 |
| Financing activities | ||||
| Dividends paid | -$13.52 | -$41.96 | -$14.05 | -$14.21 |
| Sale and purchase of stock | -$158.21 | -$121.11 | ||
| Net borrowings | -$11.37 | -$88.37 | ||
| Total cash flows from financing | -$182.32 | -$311.63 | -$223.71 | -$105.89 |
| Effect of exchange rate | $2.56 | $0.49 | $0.73 | $1.65 |
| Change in cash and equivalents | $33.83 | -$20.2 | -$29.73 | $8.2 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $717.79 | $675.61 | $991.59 | $943.95 |
| Operating activities | ||||
| Depreciation | $568.04 | $581.86 | $533.21 | $510.49 |
| Business acquisitions & disposals | $20.46 | -$8.31 | -$60.26 | -$49.41 |
| Stock-based compensation | $87.72 | $85.38 | $73.69 | $65.84 |
| Total cash flows from operations | $1267.8 | $996.02 | $883.7 | $2360.17 |
| Investing activities | ||||
| Capital expenditures | -$743.05 | -$734 | -$855.66 | -$731.31 |
| Investments | -$40.7 | $94.91 | $1.36 | -$21.74 |
| Total cash flows from investing | -$763.27 | -$647.3 | -$914.47 | -$802.56 |
| Financing activities | ||||
| Dividends paid | -$55.48 | -$58.45 | -$65.9 | -$17.34 |
| Sale and purchase of stock | -$533.71 | -$818.85 | -$1207.5 | -$194.4 |
| Net borrowings | $99.62 | $615.95 | $217.11 | -$160.97 |
| Total cash flows from financing | -$493.94 | -$318.4 | -$1068.95 | -$384.86 |
| Effect of exchange rate | $3.06 | -$8.42 | -$0.5 | $0.74 |
| Change in cash and equivalents | $13.63 | $21.9 | -$1100.22 | $1173.49 |
News
|
Premium Growth Propels Humana (HUM) to Easy Q1 Earnings Beat
Zacks via Yahoo Finance
24 Apr 2024
|
|
Watch These 5 Medical Stocks for Q1 Earnings: Beat or Miss?
Zacks via Yahoo Finance
23 Apr 2024
|
|
Should You Buy HCA Healthcare (HCA) Ahead of Q1 Earnings?
Zacks via Yahoo Finance
23 Apr 2024
|
|
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Zacks via Yahoo Finance
22 Apr 2024
|
|
Will Acute Care Unit Aid Universal Health's (UHS) Q1 Earnings?
Zacks via Yahoo Finance
19 Apr 2024
|
|
Will Humana (HUM) Q1 Earnings Beat on CenterWell Strength?
Zacks via Yahoo Finance
19 Apr 2024
|
|
5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings
Zacks via Yahoo Finance
19 Apr 2024
|
|
Will High Medical Care Ratios Hurt Molina's (MOH) Q1 Earnings?
Zacks via Yahoo Finance
19 Apr 2024
|
|
Elevance (ELV) Q1 Earnings Beat on Rate Hikes, Guidance Raised
Zacks via Yahoo Finance
18 Apr 2024
|
|
Will Low Patient Days Impact Community Health (CYH) Q1 Earnings?
Zacks via Yahoo Finance
18 Apr 2024
|
Fundamentals
| Market cap | $11.08B |
|---|---|
| Enterprise value | $16.33B |
| Shares outstanding | 67.18M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 7.44% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 1.80 |
| Book/Share | 91.39 |
| Cash/Share | 1.78 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.26 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.40 |
| Quick ratio | 1.29 |